SEER Cancer Statistics Review 1975-2007National Cancer Institute

Devcan Version 6.5.0, April 2010, National Cancer Institute (http://srab.cancer.gov/devcan/ ).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,

Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005. All Races Whites Blacks Site Percent ( 95% C.I. ) Percent ( 95% C.I. ) Percent ( 95% C.I. )

All Sites 40 .77 ( 40 .67, 40 .86 ) 41.23 ( 41.13, 41.34 ) 36 .46 ( 36 .17, 36 .75 ) Invasive and In Situ 43 .61 ( 43 .51, 43 .71 ) 44.13 ( 44.02, 44.24 ) 38 .15 ( 37 .86, 38 .45 ) Oral Cavity and Pharynx 1.02 ( 1.01, 1.04 ) 1.05 ( 1.04, 1.07 ) 0 .79 ( 0 .75, 0 .83 ) Esophagus 0 .50 ( 0 .49, 0 .51 ) 0 .52 ( 0 .51, 0 .53 ) 0 .46 ( 0 .43, 0 .50 ) Stomach 0 .88 ( 0 .86, 0 .89 ) 0 .76 ( 0 .75, 0 .78 ) 1.12 ( 1.07, 1.17 ) Colon and Rectum 5 .12 ( 5 .09, 5 .16 ) 5 .09 ( 5 .05, 5.13 ) 5.05 ( 4.94, 5.15 ) Invasive and In Situ 5 .37 ( 5 .33, 5 .40 ) 5 .32 ( 5 .29, 5.36 ) 5.33 ( 5.22, 5.44 ) Liver and Intrahepatic Bile Duct 0 .76 ( 0 .75, 0 .77 ) 0 .65 ( 0 .64, 0 .67 ) 0 .76 ( 0 .73, 0 .80 )
Pancreas 1.41 ( 1.39, 1.43 ) 1.40 ( 1.38, 1.42 ) 1.50 ( 1.44, 1.56 ) Larynx 0 .36 ( 0 .35, 0 .37 ) 0 .37 ( 0 .36, 0 .38 ) 0 .46 ( 0 .43, 0 .49 ) Invasive and In Situ 0 .39 ( 0 .38, 0 .40 ) 0 .40 ( 0 .39, 0 .41 ) 0 .48 ( 0 .45, 0 .51 ) Lung and Bronchus 6 .95 ( 6 .91, 6 .99 ) 7 .15 ( 7 .11, 7 .19 ) 6 .53 ( 6 .41, 6 .65 ) Melanoma of the Skin 1.93 ( 1.91, 1.95 ) 2 .24 ( 2 .22, 2 .27 ) 0 .09 ( 0 .07, 0 .10 ) Invasive and In Situ 3 .10 ( 3 .08, 3 .13 ) 3 .55 ( 3 .52, 3 .58 ) 0 .10 ( 0 .09, 0 .12 )
Breast 6 .29 ( 6 .26, 6 .33 ) 6 .47 ( 6 .43, 6 .51 ) 5.41 ( 5.30, 5.51 ) Invasive and In Situ 7 .53 ( 7 .49, 7 .57 ) 7 .71 ( 7 .66, 7 .75 ) 6 .52 ( 6 .40, 6 .63 ) Urinary Bladder (Invasive and In Situ) 2 .39 ( 2 .37, 2 .42 ) 2 .59 ( 2 .56, 2 .62 ) 1.18 ( 1.13, 1.23 ) Kidney and Renal Pelvis 1.49 ( 1.47, 1.51 ) 1.55 ( 1.53, 1.57 ) 1.34 ( 1.29, 1.40 ) Brain and Other Nervous System 0 .61 ( 0 .59, 0 .62 ) 0 .66 ( 0 .65, 0 .68 ) 0 .32 ( 0 .29, 0 .34 ) Thyroid 0 .90 ( 0 .89, 0 .91 ) 0 .94 ( 0 .92, 0 .95 ) 0 .52 ( 0 .49, 0 .55 ) Hodgkin Lymphoma 0 .23 ( 0 .23, 0 .24 ) 0 .25 ( 0 .24, 0 .26 ) 0 .20 ( 0 .18, 0 .22 ) Non-Hodgkin Lymphoma 2 .10 ( 2 .08, 2 .12 ) 2 .21 ( 2 .19, 2 .24 ) 1.20 ( 1.15, 1.25 ) Myeloma 0 .64 ( 0 .63, 0 .65 ) 0 .60 ( 0 .59, 0 .61 ) 1.05 ( 1.00, 1.10 ) Leukemia 1.30 ( 1.28, 1.31 ) 1.37 ( 1.35, 1.39 ) 0 .82 ( 0 .78, 0 .87 ) Acute Lymphocytic Leukemia 0 .13 ( 0 .12, 0 .13 ) 0 .14 ( 0 .13, 0 .14 ) 0 .07 ( 0 .06, 0 .08 ) Chronic Lymphocytic Leukemia 0 .48 ( 0 .47, 0 .49 ) 0 .51 ( 0 .50, 0 .52 ) 0 .26 ( 0 .24, 0 .29 ) Acute Myeloid Leukemia 0 .38 ( 0 .37, 0 .39 ) 0 .39 ( 0 .38, 0 .40 ) 0 .27 ( 0 .24, 0 .29 ) Chronic Myeloid Leukemia 0 .16 ( 0 .15, 0 .16 ) 0 .16 ( 0 .16, 0 .17 ) 0 .12 ( 0 .11, 0 .14 ) Kaposi Sarcoma 0 .05 ( 0 .05, 0 .05 ) 0 .04 ( 0 .04, 0 .05 ) 0 .08 ( 0 .07, 0 .10 ) Mesothelioma 0 .12 ( 0 .12, 0 .13 ) 0 .14 ( 0 .13, 0 .14 ) 0 .06 ( 0 .05, 0 .07 ) Table 1.14

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2005-2007SEER Cancer Statistics Review 1975-2007National Cancer Institute

Devcan Version 6.5.0, April 2010, National Cancer Institute (http://srab.cancer.gov/devcan/ ).

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,

Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Note: Invasive cancer only unless specified otherwise.

a Underlying incidence data for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area)

counties. b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005. Asian/Pacific American Indian/ Islanders Alaska Nativesa Hispanicsb Site Percent ( 95% C.I. ) Percent ( 95% C.I. ) Percent ( 95% C.I. )

All Sites 34.98 ( 34.60, 35 .37 ) 27 .78 ( 26 .61, 29 .09 ) 35.58 ( 35.24, 35.92 ) Invasive and In Situ 36 .93 ( 36 .55, 37 .33 ) 29 .00 ( 27 .78, 30 .35 ) 37 .24 ( 36 .89, 37 .59 ) Oral Cavity and Pharynx 0 .85 ( 0 .80, 0 .91 ) 0 .66 ( 0 .52, 1.00 ) 0 .67 ( 0 .63, 0 .72 ) Esophagus 0 .34 ( 0 .30, 0 .39 ) 0 .46 ( 0 .33, 0 .80 ) 0 .34 ( 0 .31, 0 .38 ) Stomach 1.90 ( 1.81, 2 .00 ) 1.19 ( 0 .93, 1.63 ) 1.43 ( 1.36, 1.50 ) Colon and Rectum 5 .22 ( 5 .06, 5 .38 ) 4.15 ( 3 .71, 4.75 ) 4.61 ( 4.48, 4.75 ) Invasive and In Situ 5 .41 ( 5 .25, 5 .57 ) 4.36 ( 3 .91, 4.96 ) 4.80 ( 4.67, 4.94 ) Liver and Intrahepatic Bile Duct 1.87 ( 1.78, 1.96 ) 1.00 ( 0 .81, 1.37 ) 1.31 ( 1.25, 1.39 )
Pancreas 1.48 ( 1.39, 1.58 ) 1.19 ( 0 .95, 1.60 ) 1.51 ( 1.43, 1.60 ) Larynx 0 .15 ( 0 .12, 0 .18 ) 0 .17 ( 0 .10, 0 .49 ) 0 .27 ( 0 .25, 0 .30 ) Invasive and In Situ 0 .16 ( 0 .14, 0 .19 ) 0 .18 ( 0 .10, 0 .49 ) 0 .29 ( 0 .27, 0 .33 ) Lung and Bronchus 5 .55 ( 5 .39, 5 .72 ) 4.74 ( 4.23, 5.40 ) 4.12 ( 4.01, 4.25 ) Melanoma of the Skin 0 .16 ( 0 .14, 0 .19 ) 0 .36 ( 0 .25, 0 .68 ) 0 .48 ( 0 .44, 0 .53 ) Invasive and In Situ 0 .22 ( 0 .19, 0 .25 ) 0 .55 ( 0 .41, 0 .89 ) 0 .68 ( 0 .63, 0 .73 )
Breast 5 .12 ( 5 .00, 5 .25 ) 3 .57 ( 3 .22, 4.08 ) 4.77 ( 4.66, 4.89 ) Invasive and In Situ 6 .38 ( 6 .24, 6 .52 ) 4.09 ( 3 .71, 4.61 ) 5.61 ( 5.50, 5.74 ) Urinary Bladder(Invasive and In Situ) 1.37 ( 1.29, 1.46 ) 0 .72 ( 0 .55, 1.07 ) 1.49 ( 1.41, 1.57 ) Kidney and Renal Pelvis 0 .95 ( 0 .89, 1.02 ) 1.68 ( 1.44, 2 .09 ) 1.55 ( 1.49, 1.62 ) Brain and Other Nervous System 0 .40 ( 0 .36, 0 .45 ) 0 .34 ( 0 .25, 0 .65 ) 0 .53 ( 0 .49, 0 .57 ) Thyroid 0 .98 ( 0 .93, 1.03 ) 0 .45 ( 0 .35, 0 .76 ) 0 .81 ( 0 .77, 0 .86 ) Hodgkin Lymphoma 0 .12 ( 0 .10, 0 .15 ) 0 .07 ( 0 .04, 0 .39 ) 0 .23 ( 0 .21, 0 .26 ) Non-Hodgkin Lymphoma 1.68 ( 1.60, 1.78 ) 1.22 ( 1.00, 1.62 ) 1.99 ( 1.91, 2 .07 ) Myeloma 0 .49 ( 0 .44, 0 .55 ) 0 .50 ( 0 .30, 0 .90 ) 0 .64 ( 0 .59, 0 .69 ) Leukemia 0 .84 ( 0 .78, 0 .91 ) 0 .59 ( 0 .46, 0 .92 ) 1.02 ( 0 .97, 1.08 ) Acute Lymphocytic Leukemia 0 .11 ( 0 .09, 0 .14 ) 0 .07 ( 0 .04, 0 .38 ) 0 .19 ( 0 .17, 0 .21 ) Chronic Lymphocytic Leukemia 0 .15 ( 0 .12, 0 .19 ) 0 .12 ( 0 .07, 0 .44 ) 0 .23 ( 0 .20, 0 .27 ) Acute Myeloid Leukemia 0 .38 ( 0 .34, 0 .43 ) 0 .23 ( 0 .15, 0 .54 ) 0 .32 ( 0 .29, 0 .35 ) Chronic Myeloid Leukemia 0 .10 ( 0 .09, 0 .13 ) 0 .10 ( 0 .05, 0 .42 ) 0 .14 ( 0 .12, 0 .17 ) Kaposi Sarcoma 0 .02 ( 0 .01, 0 .04 ) 0 .03 ( 0 .01, 0 .35 ) 0 .09 ( 0 .07, 0 .11 ) Mesothelioma 0 .05 ( 0 .04, 0 .07 ) 0 .07 ( 0 .03, 0 .38 ) 0 .12 ( 0 .10, 0 .15 ) Table 1.14 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Both Sexes, 17 SEER Areas, 2005-2007